Evidence map›Paper›PMID 33034095›Full record

Trial reportJournal of internal medicine2021

Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.

M L L Madariaga, J J Guthmiller, S Schrantz, M O Jansen, C Christensen, M Kumar, M Prochaska, G Wool, A Durkin-Celauro, W H Oh and 24 more

Erratum issuedOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 8 pooled it
1.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 8 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 2 institutions in 1 country.

M L L MadariagaFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-2950-7230
J J GuthmillerDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
S SchrantzDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
M O JansenDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
C ChristensenDepartment of, Pathology, University of Chicago, Chicago, IL, USA.
M KumarDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
M ProchaskaDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
G WoolDepartment of, Pathology, University of Chicago, Chicago, IL, USA.
A Durkin-CelauroFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
W H OhFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
L TrockmanFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
J VigneswaranFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
R KeskeyFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
D G ShawCommittee on Immunology, University of Chicago, Chicago, IL, USA.
H DuganCommittee on Immunology, University of Chicago, Chicago, IL, USA.
N-Y ZhengDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
M CobbDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
H UtsetDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
J WangDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
O StovicekDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
C BethelClinical Microbiology and Immunology Laboratory, University of Chicago, Chicago, IL, USA.
S MatushekClinical Microbiology and Immunology Laboratory, University of Chicago, Chicago, IL, USA.
M GiurcanuDepartment of Public Health Sciences, University of Chicago, Chicago, IL, USA.
K G BeavisBiological Sciences Division, Department of Pathology, University of Chicago, Chicago, IL, USA.
D di SabatoFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
D MeltzerDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
M K FergusonFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
J P KressDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
K ShanmugarajahFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
J B MatthewsFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
J F FungFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
P C WilsonDepartment of, Medicine, University of Chicago, Chicago, IL, USA.
J C AlverdyFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
J S DoningtonFrom the, Departments of, Department of, Surgery, University of Chicago, Chicago, IL, USA.
University of Chicago · USChicago Department of Public Health · US

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
RESEARCH TRAINING IN RESPIRATORY BIOLOGYT32HL007605 · NHLBI · UNIVERSITY OF CHICAGO · PI Yun Fang, Gokhan M. Mutlu · 1985 to 2026
$18.1M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007090 · NIAID · UNIVERSITY OF CHICAGO · PI Peter Aidan Savage · 1985 to 2026
$11.7M
Department of Surgery University of ChicagoNational Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051NHLBI NIH HHS T32 HL007605NIAID NIH HHS 75N93019C00051NIAID NIH HHS T32 AI007090
6 · The paper itself

Abstract

backgroundConvalescent plasma therapy for COVID-19 relies on transfer of anti-viral antibody from donors to recipients via plasma transfusion. The relationship between clinical characteristics and antibody response to COVID-19 is not well defined. We investigated predictors of convalescent antibody production and quantified recipient antibody response in a convalescent plasma therapy clinical trial.

methodsMultivariable analysis of clinical and serological parameters in 103 confirmed COVID-19 convalescent plasma donors 28 days or more following symptom resolution was performed. Mixed-effects regression models with piecewise linear trends were used to characterize serial antibody responses in 10 convalescent plasma recipients with severe COVID-19.

resultsDonor antibody titres ranged from 0 to 1 : 3892 (anti-receptor binding domain (RBD)) and 0 to 1 : 3289 (anti-spike). Higher anti-RBD and anti-spike titres were associated with increased age, hospitalization for COVID-19, fever and absence of myalgia (all P < 0.05). Fatigue was significantly associated with anti-RBD (P = 0.03). In pairwise comparison amongst ABO blood types, AB donors had higher anti-RBD and anti-spike than O donors (P < 0.05). No toxicity was associated with plasma transfusion. Non-ECMO recipient anti-RBD antibody titre increased on average 31% per day during the first three days post-transfusion (P = 0.01) and anti-spike antibody titre by 40.3% (P = 0.02).

conclusionAdvanced age, fever, absence of myalgia, fatigue, blood type and hospitalization were associated with higher convalescent antibody titre to COVID-19. Despite variability in donor titre, 80% of convalescent plasma recipients showed significant increase in antibody levels post-transfusion. A more complete understanding of the dose-response effect of plasma transfusion amongst COVID-19-infected patients is needed.

Indexed as

Antibodies, ViralAntibody FormationCOVID-19COVID-19 Serological TestingSARS-CoV-2Symptom AssessmentAdultAgedAntibodies, NeutralizingCOVID-19 SerotherapyFemaleHumansImmunization, PassiveImmunoglobulin GMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Gantibody titreconvalescent plasmaCOVID-19

Identifiers

PMID33034095
PMCPMC7675325
OpenAlexW3037076058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.